The CDKN2 gene is located on the short arm of chromosome 9p and encodes two unrelated proteins, p16
Many different pathways and proteins are involved in the regulation of the cell cycle. The CDKN2 gene on the short arm of chromosome 9p, frequently deleted in many human cancer cell lines, encodes two different cell cycle regulatory proteins, p16 INK4a and ARF (murine p19 ARF , human p14 ARF ). 1) p16 INK4a and p14 ARF have different first exons (exon 1α for p16 INK4a and exon 1β for p14 ARF ) and share common exons, exon 2 and exon 3. They use different reading frames to translate two distinct proteins. 2, 3) This genetic arrangement is unusual in mammalian cells. 4, 5) p16 INK4a and p14 ARF play an important role in independent cell cycle regulatory pathways, the retinoblastoma pathway and the p53 pathway, respectively. p16 INK4a is a tumor suppressor, which specifically inhibits cyclin-dependent kinases, CDK4 and CDK6. 6) Several observations indicate an important role of p16
INK4a in the development of many tumors. Mutations are frequently observed in melanomas, including familial types, 7, 8) and head and neck squamous cell carcinomas. 9) While homozygous deletions are a common event in some types of human cancers and cancer cell lines, 6) such alterations are infrequent in the majority of solid tumors. However, hypermethylation of p16
INK4a promoter can occur with more tumorspecific patterns than found for homozygous deletions. [10] [11] [12] [13] The other protein, p14 ARF , also functions as a growth suppressor. p14 ARF overexpression induces G1/S and G2/ M cell cycle arrest by a mechanism distinct from that of the CDK inhibition. 14) Recent studies have suggested that p14 ARF interacts in vivo with MDM2 and neutralizes MDM2-mediated inhibition of p53. 1, [15] [16] [17] Mutations in shared exons 2 and 3 have been demonstrated in some tumors, 6, 18) while no point mutations in the specific exon 1β of p14 ARF have been reported. Specific deletion of exon 1β has been described in melanoma cell lines 19) and genomic alterations of p14 ARF are found in some T-cell acute lymphocytic leukemias. 20) However, the deletion of p14 ARF also targets p16 INK4a in the majority of cases. Recent studies demonstrated that hypermethylation of the human p14
ARF promoter is independent of that of p16
INK4a
promoter in some cancer cell lines and human cancers. 21, 22) Thus, hypermethylation of p14 ARF promoter may be associated with p14
ARF inactivation in some human tumors. (Table I) . RNA extraction Total RNA was extracted from freshly frozen tissue samples using ISOGEN (Nippon Gene, Toyama) according to the manufacturer's recommendations.
Competitive RT-PCR To compare relative levels of p16 INK4a and p14 ARF transcripts we performed competitive RT-PCR. Competitive RT-PCR was carried out using Ready-To-Go RT-PCR Beads (Amersham Pharmacia Biotech, Foster City, CA) according to the Two-Step Protocol recommended by the manufacturer. Two hundred nanograms of total RNA was subjected to reverse transcription using oligo(dT) primer in a 50 µl reaction volume for 30 min at 42°C. The following primers were then added for PCR, in exon 1α (sense 1) 5′-GGA GGC CGA TCC AGG TCA-3′, exon 1β (sense 2) 5′-TGT GGC CCT CGT GCT GAT-3′ and exon 2 (antisense) 5′-ACC ACC AGC GTG TCC AGG AA-3′. PCR conditions were as follows: 95°C for 5 min, 32 cycles of 94°C for 60 s, 58°C for 60 s, and 72°C for 90 s, followed by incubation at 72°C for 5 min. PCR conditions were determined from the cycle curve and RNA concentration curve. Ten microliters of each product was run on a 2% agarose gel, and the bands were visualized by 10 mg/ml ethidium bromide staining for 15 min. As an internal control, a fragment of human GAPDH was amplified from parallel samples by PCR using the following primers: (sense), 5′-CGG AGT CAA CGG ATT TGG TCG TAT-3′; and (antisense), 5′-AGC CTT CTC CAT GGT GGT GAA GAC-3′, for 22 cycles of 94°C for 60 s, 58°C for 60 s, and 72°C for 60 s. To rule out the possibility of false positives, competitive RT-PCR was performed at least twice in independent experiments.
Evaluation of p16
INK4a and p14 ARF expression The intensities of p16
INK4a and p14 ARF bands were quantified using NIH Image. The relationship between the ratio of the intensity of p16
INK4a to p14 ARF band and clinicopathological characteristics was examined. Statistical analyses Associations between categorical variables were analyzed by Mann-Whitney's U test, P value: Fisher's exact probability test.
Fisher's exact probability test and simple linear regression (Stat View 4.0). All tests were two-sided and the criterion of significance was P<0.05.
RESULTS
Competitive RT-PCR We investigated the expression of p16 INK4a and p14 ARF using competitive RT-PCR in 60 tumors and matching normal lung tissues from the same patients. Using specific sense primers in exon 1α and exon 1β and a common reverse primer in exon 2, both transcripts were amplified simultaneously in a single reaction. This allowed us to compare directly the amounts of transcripts of p16
INK4a and p14
ARF
. As shown in Fig. 1 , the expression levels of p16
INK4a in the normal lung tissues (n=60) were similar, and the intensities of the p16
INK4a and p14 ARF bands were nearly equal or p16 INK4a expression slightly exceeded that of p14 ARF . In most tumor samples, the intensities of the p16
INK4a and p14 ARF bands were different from those in the corresponding normal lung tissues. In 38 cases the intensity of the p16
INK4a band was similar to or slightly weaker than that of p14 ARF (represented by patient 1 in Fig. 1 ). In 6 cases the intensity of the p16
INK4a band was weaker than that of p14 ARF , but the band of p16
INK4a was clearly visible (represented by patient 3). In 15 cases the intensity of p16
INK4a band was much weaker than that of p14 ARF and the band of p16 INK4a was barely visible (represented by patients 4 and 5). In only one tumor was the intensity of p16
INK4a band much stronger than that of p14 ARF , and the band of p14 ARF was barely visible (patient 2). In cases such as patients 4, 5, or 2 in Fig. 1 , it is possible that the band of one product may have obscured the other product because of the competition in the PCR. We also performed the RT-PCR for p16
INK4a and p14 ARF separately for each of these patients. The intensity of the bands in the competitive RT-PCR correlated reasonably well with that of RT-PCR performed separately (data not shown). Thus, the faint band in the competitive RT-PCR actually represents a small amount of transcript.
Ratio of the intensity of p16
INK4a to p14 ARF band and clinicopathological characteristics in NSCLCs We next analyzed the relationship between the ratio of the intensity of p16
INK4a to p14 ARF band and clinicopathological characteristics. The p stage II-IV tumors had significantly lower p16
INK4a to p14 ARF ratios than the p stage I tumors (Fig. 2) . INK4a to the p14 ARF band according to p stage of NSCLCs. The boxes represent 75% confidence interval; the long horizontal line, the median; the short horizontal bars, 90% confidence interval. Statistical analysis by Mann-Whitney's U test.
Fig. 3. Ratio of intensity of the p16
INK4a to the p14 ARF band according to tumor status of NSCLCs. Symbols are the same as in the legend to Fig. 2 .
The T2-4 tumors had significantly lower p16
INK4a to p14 ARF ratios than the T1 tumors (Fig. 3) . The N1-3 tumors had significantly lower p16
INK4a to p14 ARF ratios than the N0 tumors (Fig. 4) . We also examined the relationship between clinicopathological characteristics and p16
INK4a or p14 ARF separately using each of the bands in the competitive RT-PCR assay. Tendencies toward lower intensity of the p16
INK4a band were observed in the p stage II-IV tumors as compared with the p stage I tumors (P=0.059) and in the T2-4 tumors as compared with the T1 tumors (P=0.056). The N1-3 tumors had a significantly lower intensity of the p16 INK4a band than the N0 tumors (P=0.037). There was no difference in the p stage, in the T status, or in the N status with regard to the intensity of the p14 ARF band (data not shown). Then we classified these tumors into two groups according to the ratio of the intensity of p16
INK4a to p14 ARF ; group A (n=39/60: 65%), log p16/p14≥ −0.6 and group B (n=21/60: 35%), log p16/p14< −0.6 (Table I) . No difference was observed in terms of age and sex between the two groups. Group B tumors had a significantly higher p stage (P=0.006), p T factor (P=0.005), and p N factor (P=0.003) than group A tumors, but there was no difference in M factor between the two groups. There was more squamous cell carcinoma than adenocarcinoma in group B as compared with group A (P=0.033). Adenocarcinoma in group B was more poorly differentiated than that in group A (P=0.028), although the difference was not significant in squamous cell carcinoma (P=0.287). In addition, group B patients had a history of heavier smoking than group A patients (P=0.008). These results suggest that the ratio of the expression of p16
INK4a to p14 ARF tends to decrease during the progression of NSCLC.
Expression levels of p16
INK4a and p14 ARF in lung cancer with reference to those in matching normal lung tissue and its relationship with p stage Tumor to normal tissue ratio of the intensity of the p16
INK4a band was plotted against that of p14 ARF , and its relation to the p stage of the tumor was analyzed (Fig. 5) . The tumor to normal tissue ratio of the intensity of p16
INK4a band varied from −2 to 0.5. All tumors but one had a log p14 ARF INK4a correlated to a higher grade of malignancy. It should also be pointed out that tumors with decreased expression of p16
INK4a have significantly higher expression of p14 ARF (Fig. 5) .
DISCUSSION
We measured the intensity of the bands of expressed p16
INK4a and p14 ARF in 60 NSCLC samples and corresponding normal lung tissues. We took advantage of the shared exons and performed a competitive PCR so that the expression levels of these genes were directly comparable (Fig. 1) . The lower ratio of the intensity of p16
INK4a to p14 ARF band was a good indicator of increased grade of malignancy in NSCLC. The intensity ratio of p16
INK4a to 
